Men with High Skeletal Risk Are Likely to Have More Fractures After Hormonal Treatment For Prostate Cancer – New Study
Androgen Deprivation Therapy (ADT) is a treatment administered for men with prostate cancer. This is especially for men whose condition would not be appropriate for surgery and radiation.
A new study has reported that long term administration of ADT on men that already have high risk of bone fracture may likely result in them having more fractures the treatment.
The new study was conducted by researchers from The Cancer Institute of New Jersey and the findings have been published in the latest version of BJU International. The findings of this research reveals that since men with ‘high’ skeletal risk are likely to have more bone fractures after ADT treatment, the results will prompt further investigation of a patient’s baseline-risk of fracture and skeletal complication before the therapy is administered.
An article published online in the Science Daily website reveals the following details about the research:
In what is believed to be the first study to describe the impact on men with a ‘high’ risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion. The findings, published in the latest online version of BJU International, also show that men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).
Men with localized prostate cancer who have underlying health conditions often receive this type of therapy with the hope to shrink or delay growth of their cancer, because they are considered inappropriate candidates for more aggressive therapies such as surgery or radiation. Previous studies have shown an association between the receipt of ADT for prostate cancer and an increased risk of bone fracture and other skeletal complications, such as a decrease in bone mineral density. The investigators at The Cancer Institute of New Jersey further explored the impact of this treatment on men already deemed to be at high risk for fracture prior to receiving therapy.
Using the population-based Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, researchers reviewed information on demographics and tumor characteristics from 75,994 men aged 66 and older who were diagnosed as having localized prostate cancer from 1992 to 2007. All of the SEER registries hold the highest level of certification of data quality. A risk assessment scale for baseline skeletal complications — including fracture — was created, utilizing the presence of certain conditions within one year prior to cancer diagnosis. These conditions included diabetes, alcohol and cigarette use, paralysis, and liver disease.
Investigators found that during a 12-year follow up, more than 58 percent of men deemed at high fracture risk prior to treatment and 38 percent considered at low risk developed at least one fracture following ADT. The research also showed that men with a high baseline risk had a higher probability of receiving ADT (52.1 percent) compared to those with a low baseline risk (38.2 percent). It was also determined that those men receiving ADT by itself were likely to have a stronger dose than those who received ADT in combination with other treatments for their prostate cancer. Mortality risk was found to be 40 percent higher within two years after experiencing a fracture.
“Our findings suggest that treating men having a high baseline risk of fracture with long-term androgen deprivation therapy may have serious adverse consequences,” said senior author Grace Lu-Yao, PhD, MPH, cancer epidemiologist at The Cancer Institute of New Jersey and professor of medicine at Robert Wood Johnson Medical School and of epidemiology at UMDNJ-School of Public Health. “We anticipate the results of this study will prompt further examination of a patient’s baseline-risk of fracture and skeletal complications prior to administering this course of therapy.”
The authors note the use of bisphosphonates, which are effective in preventing bone loss in patients with prostate cancer receiving ADT, was not available in the SEER-Medicare linked data. Information regarding a patient’s height and weight, which can be considered risk factors for skeletal complications, also was not available. Data on men younger than 66 were not examined. Despite these limitations, Dr. Lu-Yao, says their investigation shines new light on a large subset of men who commonly receive ADT.
Conclusively, the following details about the new study on prostate cancer are revealing. It is new step in prostate cancer research. The findings are important in that they help researchers to take invaluable steps in monitoring the bone fracture risks of patients administered with androgen deprivation therapy (ADT). Read the full article published in the January 17, 2013 in Science Daily.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- High Choline-Rich Food Intake Can Result to High Risk of Lethal Prostate Cancer
- Fizzy Drinks Increase Risk of Aggressive Prostate Cancer in Men – Study
- Prostate Cancer Treatment Regret is High in Men with Cardiovascular Disease
- Efficacy Of Hormonal Treatment In Prostate Cancer
- High-Risk Localized Prostate Cancer to be eliminated by Abiraterone Acetate
- Radiation Treatment after Prostatectomy Improves Prostate Cancer Results for Men – Study
- High Fat Diet May Promote Prostate Cancer – A Japanese Study
- Study Reveals High Fiber Diet Reduces Progression of Prostate Cancer
- Prostate Cancer Hormonal Treatment
- High Consumption of Eggs, Chicken and Red Meat Expose Healthy Men with Risks of Advanced Prostate Cancer
- Prostate Cancer Hormonal Treatment
- Prostate Cancer Hormonal Treatment and Radiation Therapy
- Hormonal Therapy For Prostate Cancer – A Treatment Worth Having
- How Red Meat is Cooked and How it is Consumed Increase The Risk Of Prostate Cancer – A New Study
- Metabolic Syndrome Increases the Risks of Death in Men with Prostate Cancer – Study